Montgomery Stuart A
Imperial College School of Medicine, University of London, PO Box 8751, W13 8WH, UK.
Expert Opin Pharmacother. 2006 Oct;7(15):2139-54. doi: 10.1517/14656566.7.15.2139.
Pregabalin is a new anxiolytic that has been recently licensed for the treatment of generalised anxiety disorder (GAD) in Europe. Short-term efficacy is based on six positive placebo-controlled studies, all of which showed a significant early separation from placebo in all of the doses used (150-600 mg) at the first week, and the efficacy at the end of the treatment was comparable with the comparators used in four of these studies. Pregabalin was effective in more or less severe GAD, on psychic and somatic symptoms of GAD, and in treating the subsyndromal depressive symptoms of GAD. Efficacy in the elderly was shown in a separate placebo-controlled study. The effect on cognitive function was minimal and notably less than that observed with benzodiazepines. The discontinuation symptoms following abrupt treatment cessation were similar to the rates with serotonin-noradrenaline re-uptake inhibitors and lower than with benzodiazepines with no signals of tolerance or dependence.
普瑞巴林是一种新型抗焦虑药，最近在欧洲已获许可用于治疗广泛性焦虑障碍（GAD）。短期疗效基于六项阳性安慰剂对照研究，所有这些研究均表明，在第一周使用的所有剂量（150 - 600毫克）下，与安慰剂相比均有显著的早期分离，并且在四项此类研究中，治疗结束时的疗效与所用对照药物相当。普瑞巴林对各种严重程度的广泛性焦虑障碍均有效，对广泛性焦虑障碍的精神和躯体症状有效，且对广泛性焦虑障碍的亚综合征性抑郁症状也有效。在一项单独的安慰剂对照研究中显示了其对老年人的疗效。对认知功能的影响极小，明显小于苯二氮䓬类药物。突然停药后的戒断症状发生率与5-羟色胺-去甲肾上腺素再摄取抑制剂相似，且低于苯二氮䓬类药物，未出现耐受性或依赖性迹象。
